VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who fail venetoclax-based salvage therapies, commenting on poor prognosis. Dr Zucenka reports that venetoclax re-initiation or low-dose cytarabine plus glasdegib may be possible options for patients in this subgroup. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter